E2F1 Overexpression Correlates with Thymidylate Synthase and Survivin Gene Expressions and Tumor Proliferation in Non–Small-Cell Lung Cancer

Purpose: We investigated the clinical significance of E2F1 gene expression in relation to its target genes, thymidylate synthase (TS) and Survivin, in case of non–small-cell lung cancer (NSCLC). Experimental Design: One hundred twenty-seven cases of resected NSCLC were analyzed. Quantitative reverse transcription-PCR was done to evaluate the gene expression of E2F1, TS, and Survivin. Immunohistochemistry was done to investigate the protein expression of E2F1, TS, and Survivin. The Ki-67 proliferation index and the apoptotic index using the terminal deoxyribonucleotidyl transferase–mediated dUTP nick-end labeling method were also evaluated. Results:E2F1 gene expression significantly correlated with the Ki-67 proliferation index (r = 0.487; P < 0.0001), although no correlation was observed between E2F1 gene expression and the apoptotic index. With regard to E2F1 target genes, E2F1 gene expression significantly correlated with TS gene expression (r = 0.709; P < 0.0001) and Survivin gene expression (r = 0.403; P < 0.0001). The overall survival rate was significantly lower in patients with high-E2F1 tumors than in those with low-E2F1 tumors (P = 0.0027), especially among patients with stage II to III NSCLCs (P = 0.0188). A Cox regression analysis showed that the E2F1 status was a significant prognostic factor for NSCLC patients (hazard ratio, 2.052; P = 0.0261). Conclusions: The present study revealed that E2F1 gene expression correlates with TS and Survivin gene expressions and tumor proliferation. During the progression of NSCLC, E2F1 overexpression could produce more aggressive tumors with a high proliferation rate and chemoresistance.

[1]  M. Fukushima,et al.  Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.

[2]  R. Adler.  Lung cancer: a review. , 1975, The West Indian medical journal.

[3]  T. Liu,et al.  Adenovirus‐mediated E2F‐1 gene transfer efficiently induces apoptosis in melanoma cells , 1999, Cancer.

[4]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[5]  S. Asai,et al.  Thymidylate Synthase Expression Correlates Closely with E 2 F 1 Expression in Colon Cancer 1 , 2000 .

[6]  W. Earnshaw,et al.  Chromosomal passengers and the (aurora) ABCs of mitosis. , 2001, Trends in cell biology.

[7]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[8]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[9]  M. Fukushima,et al.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT , 2006, British Journal of Cancer.

[10]  A. Papavassiliou,et al.  Distinct expression patterns of the transcription factor E2F‐1 in relation to tumour growth parameters in common human carcinomas , 2004, The Journal of pathology.

[11]  C. Cordon-Cardo,et al.  Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. , 2000, Cancer research.

[12]  W. Sellers,et al.  Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter , 1994, Molecular and cellular biology.

[13]  G. Sirugo,et al.  Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting* , 1998, The Journal of Biological Chemistry.

[14]  T. Yoshikawa,et al.  Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. , 2004, Oncology reports.

[15]  J. Nevins,et al.  The E2F1–3 transcription factors are essential for cellular proliferation , 2001, Nature.

[16]  J. Nevins,et al.  Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes , 1995, Molecular and cellular biology.

[17]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[18]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. McCourty,et al.  Immunohistochemical expression of cyclin D1, E2F‐1, and Ki‐67 in benign and malignant thyroid lesions , 2002, The Journal of pathology.

[20]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[21]  J. Nevins,et al.  Oncogenic capacity of the E2F1 gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Wada,et al.  Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer , 2001, British Journal of Cancer.

[23]  G. Scagliotti,et al.  Prognostic significance of Ki67 labelling in resected non small cell lung cancer. , 1993, European journal of cancer.

[24]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[25]  A. Huvos,et al.  mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. , 2003, Molecular cancer therapeutics.

[26]  A. Klein-Szanto,et al.  E2F-1: a proliferative marker of breast neoplasia. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  Patricia L. Harris,et al.  Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Po-Huang Lee,et al.  High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5‐fluorouracil‐based systemic chemotherapy , 1998, Cancer.

[29]  G. Milano,et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. , 1994, European journal of cancer.

[30]  W. Yung,et al.  Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo , 1998, Nature Medicine.

[31]  R. Haba,et al.  Clinical application of biological markers for treatments of resectable non-small-cell lung cancers , 2005, British Journal of Cancer.

[32]  A. Klein-Szanto,et al.  E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. , 2000, Cancer research.

[33]  D. Banerjee,et al.  Role of E2F-1 in chemosensitivity. , 1998, Cancer research.

[34]  K. Ryan,et al.  Life and death decisions by E2F-1 , 2004, Cell Death and Differentiation.

[35]  Amanda,et al.  Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. , 1980, The Journal of biological chemistry.

[36]  N. Dyson,et al.  Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. , 1998, Molecular cell.

[37]  P. Farnham,et al.  Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. , 1994, Genes & development.

[38]  K. Naka,et al.  Expression of the E2F family in human gastrointestinal carcinomas , 1999, International journal of cancer.

[39]  M. Fukushima,et al.  Tailor-made chemotherapy for non-small cell lung cancer patients. , 2006, Future oncology.

[40]  A. Papavassiliou,et al.  Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas , 2002, The Journal of pathology.

[41]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[42]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[43]  M. P. Holloway,et al.  Aberrant Regulation of Survivin by the RB/E2F Family of Proteins* , 2004, Journal of Biological Chemistry.

[44]  Yasuo Watanabe,et al.  Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. , 2002, International journal of oncology.

[45]  F. Kaye,et al.  Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.

[46]  M. Ueno,et al.  Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. , 2005, International journal of oncology.

[47]  E. Brambilla,et al.  Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma , 2001, Oncogene.

[48]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[49]  C. Cordon-Cardo,et al.  Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. , 1999, Journal of the National Cancer Institute.

[50]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.